CN1514839A - 作为抗心律失常化合物的3,7-二氮杂双环[3.3.1]制剂 - Google Patents

作为抗心律失常化合物的3,7-二氮杂双环[3.3.1]制剂 Download PDF

Info

Publication number
CN1514839A
CN1514839A CNA028116364A CN02811636A CN1514839A CN 1514839 A CN1514839 A CN 1514839A CN A028116364 A CNA028116364 A CN A028116364A CN 02811636 A CN02811636 A CN 02811636A CN 1514839 A CN1514839 A CN 1514839A
Authority
CN
China
Prior art keywords
preparation
requires
acid
diazabicyclo
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028116364A
Other languages
English (en)
Chinese (zh)
Inventor
C
C·霍夫达尔
¸
A·伦德格伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1514839A publication Critical patent/CN1514839A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA028116364A 2001-04-12 2002-04-12 作为抗心律失常化合物的3,7-二氮杂双环[3.3.1]制剂 Pending CN1514839A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE01013291 2001-04-12
SE0101329A SE0101329D0 (sv) 2001-04-12 2001-04-12 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
CN1514839A true CN1514839A (zh) 2004-07-21

Family

ID=20283785

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028116364A Pending CN1514839A (zh) 2001-04-12 2002-04-12 作为抗心律失常化合物的3,7-二氮杂双环[3.3.1]制剂

Country Status (26)

Country Link
US (1) US20050037067A1 (https=)
EP (1) EP1389212B1 (https=)
JP (1) JP2005500262A (https=)
KR (1) KR20030088498A (https=)
CN (1) CN1514839A (https=)
AR (1) AR035806A1 (https=)
AT (1) ATE332902T1 (https=)
BG (1) BG108234A (https=)
BR (1) BR0208828A (https=)
CA (1) CA2443473A1 (https=)
CZ (1) CZ20032774A3 (https=)
DE (1) DE60213084T2 (https=)
EE (1) EE200300495A (https=)
HU (1) HUP0303486A3 (https=)
IL (1) IL158033A0 (https=)
IS (1) IS6989A (https=)
MX (1) MXPA03009209A (https=)
NO (1) NO20034529L (https=)
NZ (1) NZ528561A (https=)
PL (1) PL366629A1 (https=)
RU (1) RU2003129230A (https=)
SE (1) SE0101329D0 (https=)
SK (1) SK12562003A3 (https=)
TW (1) TWI257391B (https=)
WO (1) WO2002083689A1 (https=)
ZA (1) ZA200307756B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
US20090142398A1 (en) * 2007-11-21 2009-06-04 Pharmascience Inc. Novel pharmaceutical compositions comprising a disintegration matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2014157603A1 (ja) * 2013-03-29 2014-10-02 アステラス製薬株式会社 経口投与用医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3732094A1 (de) * 1987-09-24 1989-04-06 Basf Ag Bispidinderivate als klasse iii-antiarrhythmika
US5110933A (en) * 1989-11-13 1992-05-05 Board Of Regents Of Oklahoma State University Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
DE4402933A1 (de) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
SE9704709D0 (sv) * 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
CN1147483C (zh) * 1999-04-09 2004-04-28 阿斯特拉曾尼卡有限公司 金刚烷衍生物
SE9903759D0 (sv) * 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent

Also Published As

Publication number Publication date
KR20030088498A (ko) 2003-11-19
JP2005500262A (ja) 2005-01-06
NO20034529L (no) 2003-12-08
EE200300495A (et) 2003-12-15
DE60213084T2 (de) 2007-01-11
BG108234A (bg) 2005-04-30
IS6989A (is) 2003-10-10
ATE332902T1 (de) 2006-08-15
NO20034529D0 (no) 2003-10-09
CZ20032774A3 (cs) 2004-01-14
NZ528561A (en) 2005-03-24
HUP0303486A3 (en) 2005-04-28
DE60213084D1 (de) 2006-08-24
AR035806A1 (es) 2004-07-14
MXPA03009209A (es) 2004-01-29
EP1389212A1 (en) 2004-02-18
BR0208828A (pt) 2004-03-09
WO2002083689A1 (en) 2002-10-24
CA2443473A1 (en) 2002-10-24
EP1389212B1 (en) 2006-07-12
SK12562003A3 (sk) 2004-03-02
SE0101329D0 (sv) 2001-04-12
PL366629A1 (en) 2005-02-07
US20050037067A1 (en) 2005-02-17
ZA200307756B (en) 2005-01-03
TWI257391B (en) 2006-07-01
HUP0303486A2 (hu) 2004-01-28
RU2003129230A (ru) 2005-04-10
IL158033A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
CN1269823C (zh) 作为抗心律不齐化合物的3,7－二氮杂双环[3.3.1]制剂
CN1279040C (zh) 用于治疗的莨菪烷衍生物
CN1204143C (zh) EtO2C－CH2－(R)Cgl－Aze－Pab－OH的晶形
CN101039676A (zh) 具有长贮存期的二氢蝶啶酮的输注溶液
CN1399639A (zh) 用于治疗心律失常的新型氧杂双皮丁化合物
CN1890220A (zh) 4－(3－氯－4－(环丙基氨基羰基)氨基苯氧基)－7－甲氧基－6－喹啉羧酰胺的盐或其溶剂合物的结晶及其制备方法
CN1547583A (zh) 多环鸟嘌呤磷酸二酯酶v抑制剂
CN1906180A (zh) 新的长效β－2－激动剂及其作为药物的用途
CN1462275A (zh) 膦酰基头孢烯化合物
CN1655761A (zh) 改性释放的药物制剂
CN1514839A (zh) 作为抗心律失常化合物的3,7-二氮杂双环[3.3.1]制剂
CN1655760A (zh) 速释药物制剂
CN1159004C (zh) 具有高含量n-乙酰半胱氨酸的可吞咽片剂
CN1279916C (zh) 作为抗心律失常化合物的3,7－二氮杂双环[3.3.1]制剂
CN101068550A (zh) 含有释放速度控制组分的羧酰胺人类免疫缺陷整合酶抑制剂药物制剂
CN101052631A (zh) 结晶霉酚酸钠
CN1130506A (zh) 头孢克罗的制药用配方
CN101058568A (zh) 桂哌齐特的新的药用盐及其制备方法
CN1152886C (zh) 表现出溶解速度加快的依匹乐酮晶形
CN101068533A (zh) 含有抗成核剂的药物组合物
CN1535149A (zh) 噻唑基酰胺类化合物的局部应用
CN1433427A (zh) 依匹乐酮晶型
CN1092420A (zh) 化合物
CN1178651C (zh) 冷冻干燥的噻吨酮抗肿瘤剂
CN1296408A (zh) 抑制mrp1的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned